- Home
- LCTX vs FNGR Comparison
LCTX vs FNGR Comparison
Compare LCTX & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FNGR
- Stock Information
- Founded
- LCTX 1990
- FNGR 2016
- Country
- LCTX United States
- FNGR Singapore
- Employees
- LCTX N/A
- FNGR N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FNGR Computer Software: Prepackaged Software
- Sector
- LCTX Health Care
- FNGR Technology
- Exchange
- LCTX Nasdaq
- FNGR Nasdaq
- Market Cap
- LCTX 171.8M
- FNGR 108.1M
- IPO Year
- LCTX N/A
- FNGR N/A
- Fundamental
- Price
- LCTX $0.94
- FNGR $2.07
- Analyst Decision
- LCTX Strong Buy
- FNGR
- Analyst Count
- LCTX 3
- FNGR 0
- Target Price
- LCTX $5.67
- FNGR N/A
- AVG Volume (30 Days)
- LCTX 299.1K
- FNGR 284.7K
- Earning Date
- LCTX 11-07-2024
- FNGR 10-14-2024
- Dividend Yield
- LCTX N/A
- FNGR N/A
- EPS Growth
- LCTX N/A
- FNGR N/A
- EPS
- LCTX N/A
- FNGR N/A
- Revenue
- LCTX $6,186,000.00
- FNGR $31,996,577.00
- Revenue This Year
- LCTX N/A
- FNGR $260.03
- Revenue Next Year
- LCTX $119.00
- FNGR N/A
- P/E Ratio
- LCTX N/A
- FNGR N/A
- Revenue Growth
- LCTX N/A
- FNGR N/A
- 52 Week Low
- LCTX $0.77
- FNGR $1.63
- 52 Week High
- LCTX $1.61
- FNGR $7.37
- Technical
- Relative Strength Index (RSI)
- LCTX 55.33
- FNGR 46.94
- Support Level
- LCTX $0.87
- FNGR $2.01
- Resistance Level
- LCTX $0.94
- FNGR $2.42
- Average True Range (ATR)
- LCTX 0.05
- FNGR 0.14
- MACD
- LCTX 0.01
- FNGR 0.00
- Stochastic Oscillator
- LCTX 92.20
- FNGR 18.60
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.